Editorial Notes

In this section of International Journal of Drug Regulatory Affairs, the writers or editors share their opinion on ongoing topics/News from agencies. Editorials are believed to be the heart and soul of the Journal. Each and every Journal is incomplete without the editorial section. Here the editor not only shares his or her view but also criticize and appreciate the ongoing topics.

Editorial is the only section were Journal can state its own opinions and comments on the current issues/Event/News.

We further welcome the Editorial notes from Editors/Writers in IJDRA Journal. It covers summary across globe from all health Authorities and major action in the industry.

Editorial Notes

Year/Quarter Editorial Notes Download
2017 (Q1)
  • Statement from FDA Commissioner Robert Califf, M.D. announcing FDA Oncology Centre of Excellence launch
  • FDA approves Odactra for house dust mite allergies
  • Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 17-19 January 2017
  • EMA to set up technical group in the context of the publication of clinical data
2017 (Q2)
  • FDA allows marketing of first whole slide imaging system for digital pathology
  • FDA approves new combination treatment for acute myeloid leukemia
  • Optimising safety information for medicines in Europe throughout product lifecycle
2017 (Q3)
  • EMA and FDA encourage use of innovative approaches in the development of medicines for Gaucher disease
  • EMA Revised guideline on first-in-human clinical trials
  • FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection
2017 (Q4)
  • FDA awards six grants for natural history studies in rare diseases
  • FDA permits marketing of device to treat diabetic foot ulcers
  • Crysvita, a medicine for the treatment of X-linked hypophosphataemia, recommended for conditional approval by EMA
  • Improving the availability of vaccines for animals within the EU
2018 (Q1)    
2018 (Q2)    
2018 (Q3)    
2018 (Q4)    
2019 (Q1)    
2019 (Q2)    
2019 (Q3)    
2019 (Q4)    
2020 (Q1)    
2020 (Q2)    
2020 (Q3)    
2020 (Q4)    
2021 (Q1)    
2021 (Q2)    
2021 (Q3)    
2021 (Q4)